Immunic’s private placement; Vertex’s cystic fibrosis data in young kidsnews2026-02-13T14:45:37+00:00February 13th, 2026|Endpoints News|
A pancreatic cancer approval; Seres cuts staffnews2026-02-12T15:10:19+00:00February 12th, 2026|Endpoints News|
Gubra forms venture unit; Galecto’s $275M offeringnews2026-02-11T15:02:48+00:00February 11th, 2026|Endpoints News|
Nektar posts one-year eczema success; Pfizer ends malnutrition trialnews2026-02-10T15:19:31+00:00February 10th, 2026|Endpoints News|
Galux raises $29M Series B; CSL teams up with Memonews2026-02-09T15:10:23+00:00February 9th, 2026|Endpoints News|
UniQure pauses higher doses in Fabry study; Aro shares Pompe datanews2026-02-06T15:00:12+00:00February 6th, 2026|Endpoints News|
Eisai gains Henlius therapy; LB Pharma snags $100M in fundingnews2026-02-05T14:21:19+00:00February 5th, 2026|Endpoints News|
Daiichi ends work on an ADC; Layoffs at GSK’s R&D unitnews2026-02-03T15:30:08+00:00February 3rd, 2026|Endpoints News|
Kyowa Kirin reveals side effect in trial; GSK was lone bidder for RAPTnews2026-02-02T15:22:27+00:00February 2nd, 2026|Endpoints News|
Moderna licenses Phase 3 asset to Recordati; ProMIS’ private placementnews2026-01-30T16:05:18+00:00January 30th, 2026|Endpoints News|
